CBL and myeloid neoplasm: Interestingly, CBL is known to have as targets several non‐RTKs, such as SYK, and RTKs including FLT3, KIT and FMS, as well as the oncogenic variants of those RTKs.9, 10 In myeloid neoplasms, mutations in CBL are thought to decrease turnover of these RTKs and promote growth and viability signalling.